EPS for Anika Therapeutics, Inc. (ANIK) Expected At $0.54

January 24, 2018 - By Ellis Scott

 EPS for Anika Therapeutics, Inc. (ANIK) Expected At $0.54
Investors sentiment increased to 1.42 in Q3 2017. Its up 0.28, from 1.14 in 2017Q2. It is positive, as 11 investors sold Anika Therapeutics, Inc. shares while 42 reduced holdings. 23 funds opened positions while 52 raised stakes. 12.29 million shares or 0.38% more from 12.24 million shares in 2017Q2 were reported.
Ahl Llp, a United Kingdom-based fund reported 7,890 shares. Thrivent For Lutherans holds 8,940 shares. Barclays Public Ltd Liability Corp accumulated 29,282 shares or 0% of the stock. New York State Common Retirement Fund invested in 0% or 15,400 shares. Aqr Limited Liability has 47,279 shares. Art Advsr Ltd Company has 5,703 shares for 0.02% of their portfolio. 175,710 are held by Columbia Wanger Asset Mgmt Ltd Llc. Ameriprise Finance accumulated 0% or 119,209 shares. Portolan Cap Llc reported 14,566 shares. Parametric Associates Ltd has invested 0% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK). Seaward Management Ltd Partnership reported 0.09% in Anika Therapeutics, Inc. (NASDAQ:ANIK). New Amsterdam Ptnrs Llc New York owns 64,829 shares. Voya Investment Ltd Liability Com holds 7,499 shares. 17,961 are owned by Commercial Bank Of America Corporation De. Tiaa Cref Inv Management Lc holds 0% or 38,417 shares in its portfolio.

Since October 12, 2017, it had 0 insider purchases, and 4 insider sales for $2.52 million activity.

Analysts expect Anika Therapeutics, Inc. (NASDAQ:ANIK) to report $0.54 EPS on February, 21.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $0.54 EPS. ANIK’s profit would be $7.92M giving it 27.49 P/E if the $0.54 EPS is correct. After having $0.46 EPS previously, Anika Therapeutics, Inc.’s analysts see 17.39 % EPS growth. The stock increased 0.03% or $0.02 during the last trading session, reaching $59.38. About 38,007 shares traded. Anika Therapeutics, Inc. (NASDAQ:ANIK) has risen 4.53% since January 24, 2017 and is uptrending. It has underperformed by 12.17% the S&P500.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

Among 4 analysts covering Anika Therapeutics (NASDAQ:ANIK), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Anika Therapeutics had 7 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Equal Weight” rating by First Analysis given on Friday, August 28. On Thursday, July 30 the stock rating was maintained by Northland Capital with “Outperform”. On Monday, October 12 the stock rating was initiated by Barrington Research with “Outperform”. Northland Capital maintained Anika Therapeutics, Inc. (NASDAQ:ANIK) on Friday, February 26 with “Outperform” rating. The firm has “Market Perform” rating by Northland Capital given on Wednesday, April 27. The company was upgraded on Wednesday, August 26 by Zacks.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company has market cap of $870.62 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology. It has a 28.01 P/E ratio. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

More important recent Anika Therapeutics, Inc. (NASDAQ:ANIK) news were published by: Businesswire.com which released: “Anika Reports Third Quarter 2017 Financial Results” on October 25, 2017, also Streetinsider.com published article titled: “Anika Therapeutics (ANIK) Announces HA-Based Bone Void Filer Receives FDA 510 …”, Businesswire.com published: “in Australia for the Treatment of Pain Associated with Osteoarthritis of all …” on October 16, 2017. More interesting news about Anika Therapeutics, Inc. (NASDAQ:ANIK) was released by: Nasdaq.com and their article: “Anika Therapeutics Receives FDA Nod for Bone Repair Therapy” with publication date: January 03, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: